Alzinova AB engages in the research and development of drugs for treatment of Alzheimer's disease. It focuses on the development of oligomer-directed vaccine and monoclonal antibody specifically for the synapse-damaging oligomers. The company was founded by Anders Sandberg and Thorleif Roland Hard on August 17, 2011 and is headquartered in Molndal, Sweden.